ARCHIVES

Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 5 | May 27, 2011

Download PDF Visit The Full Archive

Related Articles

Cancer Rates May Rise 50% By 2020, IARC Says

April 18, 2003

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

ASCO Recommends Beginning Palliative Care Alongside Standard Therapy in Metastatic NSCLC

February 24, 2012

CTRF Seeks Applications In Clinical Cancer Research.

January 28, 2000

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

April 27, 2012

ACS Unveils Plan For Combating Tobacco Marketing

May 18, 1990